Seikagaku Corporation

4548

JP3414000004

Pharmaceuticals

Delayed Japan Exchange Other stock markets 02:00:00 2024-04-16 am EDT			5-day change	1st Jan Change
753 ^JPY	-0.40%		-1.44%	-1.05%

Apr. 08	Ferring Pharmaceuticals Inc. Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603, in Lumbar Disc Herniation at ASIPP 2024	CI
2023	Seikagaku Corporation Reports Earnings Results for the Full Year Ended March 31, 2023	CI

Seikagaku Corporation's Equity Buyback announced on May 13, 2021 has closed with 200,000 shares, for ¥221.6 million

July 15, 2021

The company closed its plan on July 16, 2021.

Latest news about Seikagaku Corporation

Ferring Pharmaceuticals Inc. Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603, in Lumbar Disc Herniation at ASIPP 2024	Apr. 08	CI
Seikagaku Corporation Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12	CI
Tranche Update on Seikagaku Corporation's Equity Buyback Plan announced on May 13, 2022.	22-12-25	CI
Seikagaku Corporation's Equity Buyback announced on May 13, 2022, has closed with 1,725,700 shares, representing 3.10% for ¥1,499.99 million.	22-12-22	CI
Tranche Update on Seikagaku Corporation's Equity Buyback Plan announced on May 13, 2022.	22-10-02	CI
Tranche Update on Seikagaku Corporation's Equity Buyback Plan announced on May 13, 2022.	22-06-30	CI
Seikagaku Corporation announces an Equity Buyback for 2,000,000 shares, representing 3.56% for ¥1,500 million.	22-05-13	CI
Seikagaku Corporation authorizes a Buyback Plan.	22-05-12	CI
Tranche Update on Seikagaku Corporation's Equity Buyback Plan announced on May 13, 2021.	21-07-18	CI
Seikagaku Corporation's Equity Buyback announced on May 13, 2021 has closed with 200,000 shares, for ¥221.6 million	21-07-15	CI
Seikagaku Corporation announces an Equity Buyback for 200,000 shares, representing 0.35% for ¥240 million.	21-05-13	CI
Seikagaku Corporation authorizes a Buyback Plan.	21-05-12	CI
Seikagaku Corporation Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2020	21-02-05	CI
Seikagaku Corporation Provides Dividend Guidance for the Year Ending March 31, 2021	21-02-05	CI
Seikagaku Corporation Revises Earnings Guidance for the Fiscal Year Ending March 31, 2021	21-02-05	CI
Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, A Treatment of Osteoarthritis, in South Korea	20-09-29	CI
Eisai and Seikagaku Enter into Agreement for the Co-Development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China	20-04-01	CI
Seikagaku Corporation completed the acquisition of Dalton Chemical Laboratories Inc. from individuals.	20-03-23	CI
Seikagaku Corporation agreed to acquire Dalton Chemical Laboratories Inc. from individuals for CAD 41 million.	20-02-27	CI
Seikagaku Corporation Announces Consolidated Earnings Results for the Six Months Ended September 30, 2019; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2020	19-11-08	CI
SEIKAGAKU : Blue-blooded crabs at heart of pharma dispute on drug testing	19-08-01	RE
Seikagaku Corporation Reports Consolidated Earnings Results for the First Quarter Ended of June 30, 2019; Provides Consolidated Earnings Guidance for the Fiscal Year Ending of March 31, 2020; Provides Dividend Guidance for the Second Quarter of Fiscal 2019 and Full Year Ending of March 31, 2020	19-07-30	CI
Seikagaku Corporation Reports Unaudited Consolidated Earnings Results for the Year Ended March 31, 2019; Provides Earnings Guidance for the Fiscal Year Ending March 31, 2020	19-05-09	CI
Seikagaku Corporation Revises Earnings Guidance for the Fiscal Year Ending March 31, 2019	19-04-23	CI
Seikagaku Corporation Announces Consolidated Earnings Results for the Nine Months Ended Dec. 31, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019	19-02-05	CI

SEIKAGAKU CORPORATION is principally engaged in the research, development, purchase, manufacture and sale of pharmaceutical products and limulus amebocyte lysate (LAL). The Company operates in two business segments. The Pharmaceutical business segment provides hyaluronan-based medicines for joint function improvement, ophthalmic operation boosters and submucosal injection materials for endoscopes, as well as drug substances for various pharmaceuticals. The LAL business segment provides reagents for measuring endotoxin.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Seikagaku Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

756 JPY

Average target price

800 JPY

Spread / Average Target

+5.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SEIKAGAKU CORPORATION	-1.05%	267M
ELI LILLY AND COMPANY	+28.79%	676B
NOVO NORDISK A/S	+24.64%	559B
JOHNSON & JOHNSON	-5.84%	356B
MERCK & CO., INC.	+15.75%	320B
ABBVIE INC.	+4.32%	286B
ASTRAZENECA PLC	+3.25%	213B
NOVARTIS AG	+0.80%	207B
ROCHE HOLDING AG	-8.67%	199B
PFIZER, INC.	-10.00%	147B

Other Pharmaceuticals